A chronopharmacodynamic study on standard heparin, a low molecular weight heparin (nadroparin) and danaproid: establishing and comparing the daily variations of these drugs in rats.
The effects of dosing time on the anticoagulant activity of unfractionated heparin, low molecular weight heparin (nadroparin) and danaproid were investigated. The chronopharmacological comparisons of the drugs were done on the anti-Xa, anti-IIa activities and activated partial thromboplastin time assays. Several dosing times were considered and an analysis based on a population approach was adopted. Under unfractionated heparin, the pharmacological activities did not exhibit significant daily variations. In contrast, significant daily profiles were observed in all the biological assays performed with low molecular weight heparin. Anti-Xa and anti-IIa activities showed some fluctuations over a 24-hour period with a peak at noon. As for the variations of the activated partial thromboplastin time, two peaks were noted early in the morning and at the beginning of nightfall. As for danaproid, only a daytime maximum of anti-Xa activity could be found.
Abrial
D
D
Laboratoire de Biologie Animale et Appliquée, Pavillon 5 Hôpital Bellevue, Saint-Etienne, France. abrial@univ-st-etienne.fr
Blanc
A
A
Réhailia
M
M
Mismetti
P
P
Bouchut
C
C
Laporte-Simitsidis
S
S
Decousus
H
H
Buisson
B
B
D000818:Animals; D002809:Chondroitin Sulfates / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019454:Chronotherapy / Q000592:standards*; D003871:Dermatan Sulfate / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D015951:Factor Xa / Q000378:metabolism; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006493:Heparin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006497:Heparan Sulfate / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D008657:Metabolic Clearance Rate; D008954:Models, Biological; D017762:Nadroparin / Q000008:administration & dosage / Q000493:pharmacokinetics; D010314:Partial Thromboplastin Time; D011516:Prothrombin / Q000037:antagonists & inhibitors / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D015951:Factor Xa; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D006493:Heparin; D006495:Heparin, Low-Molecular-Weight; D006497:Heparan Sulfate; D017762:Nadroparin; D011516:Prothrombin; C025337:Factor IIa; C035838:danaparoid